Pharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 1, 2010, Pages 43-53

  Filopanti, M ^a   Lania, A G ^a,b   Spada, A ^b  

^a IRCCS   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Dopamine receptor; DRD2; Pituitary adenoma; Prolactin; Prolactinoma

Indexed keywords

BROMOCRIPTINE; BROMPERIDOL; CABERGOLINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; PERPHENAZINE; PROLACTIN; RISPERIDONE;

ALCOHOLISM; ALLELE; CLINICAL TRIAL; DNA POLYMORPHISM; DOPAMINE 2 RECEPTOR GENE; ENDOCRINE DISEASE; GENE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HORMONE RELEASE; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; PHARMACOGENETICS; PROTEIN BINDING; REVIEW; SCHIZOPHRENIA;

DOPAMINE AGONISTS; GENETIC VARIATION; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROLACTINOMA; RECEPTORS, DOPAMINE D2;

EID: 72949110767     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903352501     Document Type: Review

References (67)

1. Noble EP. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes [review]. Am J Med Genet B Neuropsychiatr Genet 2003;116B:103-125
2. Le Foll B, Gorelick DA, Goldberg SR Genetics of dopamine receptors drug addiction. a comprehensive review [review]. Behav Pharmacol 2009;20:1-17
3. Fitzgerald P, Dinan TG. Prolactin and dopamine: What is the connection? A review article. J Psychopharmacol 2008;22(2 Suppl.):12-19
4. Stefaneanu L, Kovacs K, Scheithauer BW, et al. Effect of dopamine agonists on lactotroph adenomas of the human pituitary. Endocr Pathol 2000;11:341-352
5. Saiardi A, Bozzi Y, Baik JH, et al. Antiproliferative role of dopamine: Loss of D2 receptors causes hormonal dysfunction and pituitary hyperplasia. Neuron 1997;19:115-126
6. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006;27:485-534
7. Filopanti M, Barbieri AM, Angioni AR, et al. Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. Pharmacogenomics J 2008;8:357-363
8. Dal Toso R, Sommer B, Ewert M, et al. The dopamine D2 receptor: Two molecular forms generated by alternative splicing. EMBO J 1989 20;8:4025-4034
9. Grandy DK, Litt M, Allen L, et al. The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. Am J Hum Genet 1989;45:778-785
10. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: A novel kinase gene closely linked to drd2 on chromosome band 11q23.1. Hum Mutat 2004;23:540-545
11. Parsian A, Fisher L, O'Malley KL, et al. A new TaqI RFLP within intron 2 of human dopamine D2 receptor gene (DRD2). Nucleic Acids Res 1991;19:6977
12. Sarkar G, Kapelner S, Grandy DK, et al. Direct sequencing of the dopamine D2 receptor (DRD2) in schizophrenics reveals three polymorphisms but no structural change in the receptor. Genomics 1991;11:8-14
13. Itokawa M, Arinami T, Futamura N, et al. A structural polymorphism of human dopamine D2 receptor, D2(Ser311?! Cys). Biochem Biophys Res Commun 1993;196:1369-1375
14. Arinami T, Gao M, Hamaguchi H, et al. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 1997;6:577-582
15. Noble EP, Blum K. Alcoholism and the D2 receptor gene [letter]. JAMA 1993;270:1547
16. Kraschewski A, Reese J, Anghelescu I, et al. Association of the dopamine D2 receptor gene will alcohol dependence: Haplotypes and subgroups of alcoholics as key factors for understanding receptor function. Pharmacogenet Genomics 2009;19:513-527
17. Berman SM, Ozkaragoz T, Noble EP, et al. Differential associations of sex and D2 dopamine receptor (DRD2) genotype with negative affect and other substance abuse risk markers in children of alcoholics. Alcohol 2003;30:201-210
18. Comings DE, Rosenthal RJ, Lesieur HR, et al. A study of the dopamine D2 receptor gene in pathological gambling. Pharmacogenetics 1996;6:223-234
19. Comings DE, Gade-Andavolu R, Gonzalez N, et al. The additive effect of neurotransmitter genes in pathological gambling. Clin Genet 2001;60:107-116
20. Hayden EP, Nurnberger JI Jr. Molecular genetics of bipolar disorder. Genes Brain Behav 2006;5:85-95
21. Bergen AW, Yeager M, Welch RA, et al. Association of multiple DRD2 polymorphisms with anorexia nervosa. Neuropsychopharmacology 2005;30:1703-1710
22. Gupta M, Chauhan C, Bhatnagar P, et al. Genetic susceptibility to schizophrenia: Role of dopaminergic pathway gene polymorphisms. Pharmacogenomics 2009;10:277-291
23. Cordeiro Q, Siqueira-Roberto J, Zung S, et al. Association between the DRD2-141C Insertion/Deletion polymorphism and schizophrenia. Arq Neuropsiquiatr 2009;67:191-194
24. Munafò MR, Timpson NJ, David SP, et al. Association of the DRD2 gene Taq1A polymorphism and smoking behavior: A meta-analysis and new data [review]. Nicotine Tob Res 2009;11:64-76
25. Wernicke C, Reese J, Kraschewski A, et al. Distinct haplogenotypes of the dopamine D2 receptor gene are associated with non-smoking behaviour and daily cigarette consumption. Pharmacopsychiatry 2009;42:41-50
26. Todt U, Netzer C, Toliat M, et al. New genetic evidence for involvement of the dopamine system in migraine with aura. Hum Genet 2009;125:265-279
27. Noble EP, Blum K, Ritchie T, et al. Allelic association of the D2 dopamine receptor gene with receptor binding characteristics in alcoholism. Arch Gen Psychiatry 1991;48:648-654
28. Thompson J, Thomas N, Singleton A, et al. D2 dopamine receptor gene (DRD2) TaqIA polymorphism: Reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997;7:479-484
29. Pohjalainen T, Rinne JO, Nagren K, et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 1998;3:256-260
30. LaruelleM, Gelernter J, Innis RB. D2 receptors binding potential is not affected by TaqI polymorphism at the D2 receptor gene. Mol Psychiatry 1998;3:261-265
31. Jonsson EG, Nothen MM, Grunhage F, et al. Polymorphisms in the dopamine D2 receptor gene and their relationship to striatal dopamine receptor density of health volunteers. Mol Psychiatry 1999;4:290-296
32. Hirvonen M, Laakso A, Nagren K, et al. C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo. Mol Psychiatry 2004;9:1060-1061
33. Hirvonen MM, Laakso A, Nagren K, et al. C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse 2009;63:907-912
34. Duan J, Wainwright MS, Comeron JM, et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genetics 2003;12:205-216
35. Zhang Y, Bertolino A, Fazio L, et al. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci USA 2007;104:20552-20557
36. Bertolino A, Fazio L, Caforio G, et al. Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. Brain 2009;131:417-425
37. Cravchik A, Sibley DR, Gejman PV. Functional analysis of the human D2 dopamine receptor missense variants. J Biol Chem 1996;271:26013-26017
38. Pohjalainen T, Cravchik A, Gejman PV, et al. Antagonist binding characteristics of the Ser311 !Cys variant of human dopamine D2 receptor in vivo and in vitro. Biochem Biophys Res Commun 1997;232:143-146
39. Muller EE. Neural control of somatotrophic function. Physiol Rev 1987;67:962-1053
40. Miyake H, Nagashima K, Onigata K, et al. Allelic variations of the D2 dopamine receptor gene in children with idiopathic short stature. J Hum Genet 1999;44:26-29
41. Arinami T, Iijima Y, Yamakawa-Kobayashi K, et al. Supportive evidence for contribution of the dopamine D2 receptor gene to heritability of stature: Linkage and association studies. Ann Hum Genet 1999;63:147-151
42. Rosmond R, Rankinen T, Chagnon M, et al. Polymorphism in exon 6 of the dopamine D2 receptor gene (DRD2) is associated with elevated blood pressure and personality disorders in men. J Hum Hyperten 2001;15:553-558
43. Rump LC, Schwertfeger MJ, Schuster U, et al. Dopamine DA2-receptor activation inhibits noradrenaline release in human kidney slices. Kidney Int 1993;43:197-204,.
44. Lawford BR, Young RM, Rowell JA, et al. Bromocriptine in the treatment of alcoholics with theD2 dopamine receptor A1 allele. Nat Med 1995;1:337-341
45. Mihara K, Kondo T, Suzuki A, et al. Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene. Psychopharmacology (Berl) 2000;149:246-250
46. Mihara K, Suzuki A, Kondo T, et al. Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromoperidol. Am J Med Genet 2001;105:271-274
47. Young RM, Lawford BR, Barnes M, et al., Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br J Psychiatry 2004;185:147-151
48. Yasui-Furukori N, Saito M, Tsuchimine S, et al. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1491-1495
49. Anderson GM, Scahill L, McCracken JT, et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 2007;61:545-550
50. Calarge CA, Ellingrod VL, Acion L, et al. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics 2009;19:373-382
51. Aklillu E, Kalow W, Endrenyi L, et al. CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics 2007;17:989-993
52. Yu AM, Idle JR, Gonzalez FJ. Polymorphic cytochrome P450 2D6: Humanized mouse model and endogenous substrates. Drug Metab Rev 2004;36:243-277
53. Fernandez A, Karavitaki N, Wass JA. Prevelence of pituitary adenomas: A comunity-based , cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol 2009;24. [Epub ahead of print]
54. Gonzalez-Iglesias AE, Murano T, Li S, et al. Dopamine inhibits basal prolactin release in pituitary lactotrophs through pertussis toxin-sensitive and -insensitive signaling pathways. Endocrinology 2008;149:1470-1479
55. Stojilkovic SS, Murano T, Gonzalez-Iglesias AE, et al. Multiple roles of Gi/o protein-coupled receptors in control of action potential secretion coupling in pituitary lactotrophs. Ann NY Acad Sci 2009;1152:174-186
56. Radl DB, Zárate S, Jaita G, et al. Apoptosis of lactotrophs induced by D2 receptor activation is estrogen dependent. Neuroendocrinology 2008;88:43-52
57. Friedman E, Adams EF, Hoog A, et al. Normal structural dopamine type 2 receptor gene in prolactin secreting and other pituitary tumors. J Clin Endocrinol Metab 1994;78:568-574
58. Caccavelli L, Morange-Ramos I, Kordon C, et al. Alteration of Ga subunits mRNA levels in bromocriptine resistant adenomas. J Neuroendocrinol 1996;8:737-746
59. Caccavelli L, Feron F, Morange I, et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine resistant prolactinomas. Neuroendocrinol 1994;60:314-322
60. Pellegrini I, Rasolonjanahary R, Gunz G, et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989;69:500-509
61. Caccavelli L, Feron F, Morange I, et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine resistant prolactinomas. Neuroendocrinol 1994;60:314-322
62. Filopanti M, Ronchi C, Ballarè E, et al. Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly. J Clin Endocrinol Metab 2005;90:4824-4828
63. Ritchie T, Noble EP. Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res 2003;28:73-82
64. Carrascosa A, Audí L, Fernández-Cancio M, et al. The exon 3-deleted/full-length growth hormone receptor polymorphism did not influence growth response to growth hormone therapy over two years in prepubertal short children born at term with adequate weight and length for gestational age. J Clin Endocrinol Metab 2008;93:764-770
65. van der Klaauw AA, van der Straaten T, Baak-Pablo R, et al. Influence of the d3-growth hormone (GH) receptor isoform on short-term and long-term treatment response to GH replacement in GH-deficient adults. J Clin Endocrinol Metab 2008;93:2828-2834
66. Ko JM, Park JY, Yoo HW. Common exon 3 polymorphism of the GH receptor (GHR) gene and effect of GH therapy on growth in Korean children with idiopathic short stature (ISS). Clin Endocrinol (Oxf) 2009;70:82-87
67. Menzaghi C, Paroni G, De Bonis C, et al. The -318 C>G single-nucleotide polymorphism in GNAI2 gene promoter region impairs transcriptional activity through specific binding of Sp1 transcription factor and is associated with high blood pressure in Caucasians from Italy. J Am Soc Nephrol 2006;17:S115-9